title: Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis.
abstract: BACKGROUND
  The administration of parnaparin sodium as oral colon-release tablets (CB-01-05 MMX) has been proposed as a novel approach for the treatment of ulcerative colitis (UC).
  
  
  OBJECTIVE
  To assess the efficacy and the tolerability of 8 weeks' oral daily administration of 210 mg of parnaparin sodium compared with placebo in subjects treated with stable-doses of oral aminosalicylates.
  
  
  METHODS
  This multicenter, randomized, double-blind proof of concept trial compared the efficacy of CB-01-05 MMX 210 mg tablets to placebo in 141 subjects with mild to moderately active left-sided UC treated with stable-doses of aminosalicylates. The efficacy was assessed by clinical activity index (CAI), endoscopic index (EI) and histological score (HS).
  
  
  RESULTS
  A total of 121 subjects (61 in test group and 60 in control group) formed the per protocol (PP) population. After 8 weeks of treatment, clinical remission was achieved in 83.6% of the CB-01-05 MMX group, and in 63.3% in the comparator group (P = 0.011). This effect was also significantly evident in the test group at week 4 (P = 0.028). A significant difference was also detected in rectal bleeding, (disappeared respectively in 75.4% and 55.0%; P = 0.018), and in mucosal friability (recovered respectively in 80.3% and in 56.7%; P = 0.005).
  
  
  CONCLUSIONS
  CB-01-05 MMX was safe and significantly effective in treating subjects with mild-to-moderate left-sided UC treated with stable-doses of aminosalicylates.
authors.affiliation: Cosmo Research and Development Srl, 20020 Lainate, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Celasco
authors.forename: A
authors.initials: A
authors.lastname: Papa
authors.forename: R
authors.initials: R
authors.lastname: Jones
authors.forename: L
authors.initials: L
authors.lastname: Moro
authors.forename: R
authors.initials: R
authors.lastname: Bozzella
authors.forename: M M
authors.initials: MM
authors.lastname: Surace
authors.forename: G C
authors.initials: GC
authors.lastname: Naccari
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D003106:Colon / Q000187:drug effects* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D003692:Delayed-Action Preparations; D006495:Heparin, Low-Molecular-Weight; C080945:parnaparin